Literature DB >> 9234527

Protection against tuberculosis by a plasmid DNA vaccine.

D B Lowrie1, C L Silva, M J Colston, S Ragno, R E Tascon.   

Abstract

Past attempts to use fractions of mycobacteria as an alternative to BCG have given disappointing results. The availability of cloned genes and suitable vectors has now opened a new avenue in which individual mycobacterial protein antigens are synthesised within transfected mammalian cells. In an ex vivo transfection approach with a retroviral vector we found that even a single antigen (hsp65) could evoke strong protection when expressed as a transgene and that expression of protection was largely a function of antigen specific cytotoxic T cells. We now find that intramuscular injection of plasmid DNA expressing the antigen from either a viral or a murine promoter can also give protection equivalent to Bacillus Calmette-Guérin (BCG). Plasmids expressing some other mycobacterial antigens, hsp70, 36 kDa and 6 kDa, are also effective, suggesting that this approach may lead to a new vaccine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234527     DOI: 10.1016/s0264-410x(97)00073-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

Review 1.  Effective vaccination against tuberculosis-a new ray of hope.

Authors:  J M Grange
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

3.  Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Authors:  D P Fonseca; B Benaissa-Trouw; M van Engelen; C A Kraaijeveld; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Co-administration of rIpaB domain of Shigella with rGroEL of S. Typhi enhances the immune responses and protective efficacy against Shigella infection.

Authors:  Sekar Tamil Selvi Chitradevi; Gurpreet Kaur; Sivaramakrishna Uppalapati; Anandprakash Yadav; Dependrapratap Singh; Anju Bansal
Journal:  Cell Mol Immunol       Date:  2015-02-02       Impact factor: 11.530

5.  Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Guérin or DNA vaccination.

Authors:  C L Silva; V L Bonato; V M Lima; L H Faccioli; S C Leão
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.

Authors:  Z Li; A Howard; C Kelley; G Delogu; F Collins; S Morris
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

Review 8.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

9.  Cytotoxic T-cell responses to Mycobacterium bovis during experimental infection of cattle with bovine tuberculosis.

Authors:  Margot A Skinner; Natalie Parlane; Allison McCarthy; Bryce M Buddle
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  Expression of Helicobacter pylori Hsp60 protein and its immunogenicity.

Authors:  Yang Bai; Liang-Ren Li; Ji-De Wang; Ye Chen; Jian-Feng Jin; Zhao-Shan Zhang; Dian-Yuan Zhou; Ya-Li Zhang
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.